In a significant development for healthcare in Australia, the Pharmaceutical Benefits Scheme (PBS) has recently added neffy® adrenaline nasal spray to its list of reimbursable treatments. This move, effective from July 1st, 2026, is a game-changer for individuals at risk of anaphylaxis, offering them a new and accessible emergency treatment option.
The Anaphylaxis Challenge
Anaphylaxis, a severe and potentially life-threatening allergic reaction, has seen a rise in cases over the past few decades. Australia, in particular, has one of the highest rates of anaphylaxis-related hospital admissions among developed nations. The statistics are alarming, with a 51% increase in emergency department presentations and a 35% rise in hospitalizations due to anaphylaxis between 2015 and 2020.
A Much-Needed Development
The listing of neffy on the PBS is a significant step forward in managing this challenging condition. Previously, this nasal spray was only available through private prescriptions, limiting its accessibility. Now, with PBS reimbursement, more Australians at risk of anaphylaxis can access this treatment, providing them with a preferred and convenient adrenaline delivery method.
Impact on Daily Lives
For those living with the risk of anaphylaxis, daily life can be a constant battle. Simple activities like dining out, attending social events, or even traveling require meticulous planning and vigilance. Parents and caregivers of children at risk face additional challenges, with even play dates and school excursions demanding extra preparation.
Expanding Treatment Options
The availability of subsidized adrenaline options, such as neffy, empowers individuals and their healthcare providers with more choice in managing anaphylaxis. As Maria Said AM, Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, highlights, "People living with severe allergies know that there is no one-size-fits-all approach to managing anaphylaxis."
Supporting Healthcare Professionals
Associate Professor Kristina Rueter, Anaphylaxis Committee Chair of ASCIA, emphasizes the importance of updated clinical guidance and educational resources. ASCIA has taken the lead in ensuring healthcare professionals have access to the latest information on anaphylaxis treatment options, including neffy. This initiative aims to provide practical and evidence-based support to clinicians managing this complex condition.
A Milestone in Access and Choice
Claire Morgan, Senior Medical Director of Pharmaceuticals at CSL Seqirus, sees the PBS listing as a significant milestone. "At CSL Seqirus, we are committed to improving access to medicines for Australian patients, and the PBS listing of this treatment option is an important step forward for people at risk of anaphylaxis," she says.
Conclusion
The addition of neffy to the PBS is a welcome development, offering a new and accessible treatment option for Australians at risk of anaphylaxis. With increased choice and improved access, individuals and their healthcare providers can better manage this challenging condition. As we continue to navigate the complexities of anaphylaxis, initiatives like these are a step towards a more inclusive and supportive healthcare system.
